Citalopram 20 mg, citalopram 40 mg and placebo in the prevention of relapse of major depression.

Dose response relationship of citalopram 20 mg, citalopram 40 mg and placebo in the treatment of moderate and severe depression.

day.

A controlled study of 20 mg famotidine nocte vs. 150 mg ranitidine nocte for the prevention of duodenal ulcer relapse.

Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial.

A double-blind placebo-controlled trial of zopiclone 7.5 mg and temazepam 20 mg in insomnia.

Daytime wakefulness following a bedtime oral dose of zolpidem 20 mg, flunitrazepam 2 mg and placebo.

Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention.

Omeprazole 20 mg three days a week and 10 mg daily in prevention of duodenal ulcer relapse. Double-blind comparative trial.

Citalopram in depression--meta-analysis of intended and unintended effects.

Testing the predictive value of peripheral gene expression for nonremission following citalopram treatment for major depression.

Selegiline-citalopram combination in patients with Parkinson's disease and major depression.

DISC1-TSNAX and DAOA genes in major depression and citalopram efficacy.

Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder.

Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study.

Acamprosate, citalopram, and alcoholism.

A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25-50 mg) in patients with major depressive disorder.

Acamprosate, citalopram, and alcoholism.

ribavirin therapy: a multicenter randomized double-blind placebo-controlled trial.

A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis.

Safety of high-dosage citalopram.

A Pilot Study of Citalopram Treatment in Preventing Relapse of Depressive Episode after Acute Treatment.

Quinidine 10 mg (NUEDEXTA(®)) for Pseudobulbar Affect.

The influence of 10 mg and 20 mg of bambuterol on the duration of succinylcholine-induced neuromuscular blockade.

Comparison of the antitussive effects of codeine phosphate 20 mg, dextromethorphan 30 mg and noscapine 30 mg using citric acid-induced cough in normal subjects.

Suggest Documents

Dose response relationship of citalopram 20 mg, citalopram 40 mg and placebo in the treatment of moderate and severe depression.

day.

A controlled study of 20 mg famotidine nocte vs. 150 mg ranitidine nocte for the prevention of duodenal ulcer relapse.

Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial.

A double-blind placebo-controlled trial of zopiclone 7.5 mg and temazepam 20 mg in insomnia.

Daytime wakefulness following a bedtime oral dose of zolpidem 20 mg, flunitrazepam 2 mg and placebo.

Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention.

Omeprazole 20 mg three days a week and 10 mg daily in prevention of duodenal ulcer relapse. Double-blind comparative trial.

Citalopram in depression--meta-analysis of intended and unintended effects.

Testing the predictive value of peripheral gene expression for nonremission following citalopram treatment for major depression.

Selegiline-citalopram combination in patients with Parkinson's disease and major depression.

DISC1-TSNAX and DAOA genes in major depression and citalopram efficacy.

Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder.

Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study.

Acamprosate, citalopram, and alcoholism.

A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25-50 mg) in patients with major depressive disorder.

Acamprosate, citalopram, and alcoholism.

ribavirin therapy: a multicenter randomized double-blind placebo-controlled trial.

A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis.

Safety of high-dosage citalopram.

A Pilot Study of Citalopram Treatment in Preventing Relapse of Depressive Episode after Acute Treatment.

Quinidine 10 mg (NUEDEXTA(®)) for Pseudobulbar Affect.

The influence of 10 mg and 20 mg of bambuterol on the duration of succinylcholine-induced neuromuscular blockade.

Comparison of the antitussive effects of codeine phosphate 20 mg, dextromethorphan 30 mg and noscapine 30 mg using citric acid-induced cough in normal subjects.

Citalopram 20 mg, citalopram 40 mg and placebo in the prevention of relapse of major depression.

Recommend Documents

Follow Us